Jun 15, 2026 · 36 min · 18 segments
Today my guest is Travis Wold from Imagenomix. What we discuss with Travis: - Alaska roots and noticing healthcare gaps - NYU origins and early breakthroughs - Tissue Failure and how it affects…
Travis WoldGuest
Dennis StrenkHost
But before that, there was this period of time where you were working in a lot of other companies.
And can we kinda go through that a little bit, and then what were the problems that you kept seeing and that kind of led you to Imagenomics?
It, and it all came-- it was a few things, right? So one, one of the beauties of liquid biopsy is, uh, there's a saying out there, the issue is with tissue, right? [chuckles] 26% of, uh-
So patients are relying on this, you're waiting 28 to 33 days, and the sample fails, and you're like, "Oh, my God, r- this would've been a good patient for a targeted therapy, wished we would've known those answers." So with Imagenomics, you can just screen that cancer slide.
We can also check for how many tumor cells or tumor tissues on that slide for adequacy, so that we know whether we can run a big panel, 500 gene plus, or maybe we have to run a really small panel.
So you think about fine needle aspirations, and it's a fantastic thing, right? You're going in with a small needle.
A lot more less invasive, a lot better recovery time, a lot less cancer material there, right?
So by the time it gets to that NGS laboratory, they don't have enough tissue to run that testing.
But before that, there was this period of time where you were working in a lot of other companies.
And can we kinda go through that a little bit, and then what were the problems that you kept seeing and that kind of led you to Imagenomics?
It, and it all came-- it was a few things, right? So one, one of the beauties of liquid biopsy is, uh, there's a saying out there, the issue is with tissue, right? [chuckles] 26% of, uh-
So patients are relying on this, you're waiting 28 to 33 days, and the sample fails, and you're like, "Oh, my God, r- this would've been a good patient for a targeted therapy, wished we would've known those answers." So with Imagenomics, you can just screen that cancer slide.
We can also check for how many tumor cells or tumor tissues on that slide for adequacy, so that we know whether we can run a big panel, 500 gene plus, or maybe we have to run a really small panel.
So you think about fine needle aspirations, and it's a fantastic thing, right? You're going in with a small needle.
A lot more less invasive, a lot better recovery time, a lot less cancer material there, right?
So by the time it gets to that NGS laboratory, they don't have enough tissue to run that testing.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
